We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

4205:TSEZeon Corporation Analysis

Data as of 2026-03-17 - not real-time

¥1,850.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Zeon Corporation trades well below its 20‑day and 50‑day moving averages, suggesting a short‑term discount relative to recent trends. Fundamentally, the company delivers a low price‑to‑earnings multiple and a price‑to‑book below parity, reinforcing the perception of undervaluation. Its dividend yield approaching four percent and a payout ratio comfortably under forty percent indicate a sustainable income stream. Operating margins are modest but positive, and revenue growth, while modest, remains in positive territory. The balance sheet shows ample cash against modest debt, supporting financial resilience. Analyst consensus leans toward a buy recommendation with a median price target modestly above the current level. Technical indicators present a mixed picture: the RSI hovers in the lower‑mid range, while the MACD histogram remains in bearish territory, yet the broader trend is classified as bullish. Volume has been stable, and the stock’s beta is low, implying limited volatility relative to the market. The combination of defensive valuation metrics and a solid dividend makes the stock attractive for income‑focused investors. However, the bearish momentum signals caution for near‑term traders. Overall, the upside potential is modest but supported by strong fundamentals and a favorable dividend profile.
Given the current support level and the absence of recent news catalysts, the near‑term outlook is cautious, but medium‑ to long‑term prospects remain positive as the company leverages its specialty chemicals niche and maintains a disciplined capital structure.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near recent support level
  • bearish MACD histogram
  • high dividend yield providing cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • valuation upside to analyst median target
  • sustainable dividend and low payout ratio
  • stable cash generation and low leverage

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • consistent profitability and solid ROE
  • defensive sector positioning with specialty chemicals demand
  • strong balance sheet and attractive yield

Key Metrics & Analysis

Financial Health

Revenue Growth1.10%
Profit Margin8.29%
P/E Ratio10.1
ROE9.69%
ROA3.75%
Debt/Equity2.47
P/B Ratio1.0

Technical Analysis

TrendBullish
RSI38.1
Support¥1,846.00
Resistance¥2,144.50
MA 20¥1,997.38
MA 50¥1,945.20
MA 200¥1,704.33
MACDBearish
VolumeStable
Fear & Greed Index79.45

Valuation

Target Price¥1,951.25
Upside/Downside5.47%
GradeUndervalued
TypeBlend
Dividend Yield3.89%

Risk Assessment

Beta0.49
Volatility35.14%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.